AR128711A1 - Métodos para tratar carcinoma microcítico de pulmón - Google Patents

Métodos para tratar carcinoma microcítico de pulmón

Info

Publication number
AR128711A1
AR128711A1 ARP230100553A ARP230100553A AR128711A1 AR 128711 A1 AR128711 A1 AR 128711A1 AR P230100553 A ARP230100553 A AR P230100553A AR P230100553 A ARP230100553 A AR P230100553A AR 128711 A1 AR128711 A1 AR 128711A1
Authority
AR
Argentina
Prior art keywords
lung carcinoma
pharmaceutically acceptable
acceptable salt
methods
wee1 inhibitor
Prior art date
Application number
ARP230100553A
Other languages
English (en)
Spanish (es)
Inventor
Imedio Esteban Rodrigo
Luke Piggott
Anne Bellon
Valerie Nicolas
Chessex Anne Vaslin
Lars Damstrup
Claudio Zanna
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of AR128711A1 publication Critical patent/AR128711A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP230100553A 2022-03-07 2023-03-07 Métodos para tratar carcinoma microcítico de pulmón AR128711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07

Publications (1)

Publication Number Publication Date
AR128711A1 true AR128711A1 (es) 2024-06-05

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100553A AR128711A1 (es) 2022-03-07 2023-03-07 Métodos para tratar carcinoma microcítico de pulmón

Country Status (12)

Country Link
US (1) US20260027117A1 (https=)
EP (1) EP4489756A1 (https=)
JP (1) JP2025509278A (https=)
KR (1) KR20240158972A (https=)
CN (1) CN118843466A (https=)
AR (1) AR128711A1 (https=)
AU (1) AU2023232376A1 (https=)
CA (1) CA3253688A1 (https=)
IL (1) IL315441A (https=)
MX (1) MX2024010900A (https=)
TW (1) TW202337469A (https=)
WO (1) WO2023170065A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608940T3 (es) 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
CN104271576A (zh) 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
AU2022287033B2 (en) 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
US20260027117A1 (en) 2026-01-29
AU2023232376A1 (en) 2024-10-10
CN118843466A (zh) 2024-10-25
KR20240158972A (ko) 2024-11-05
MX2024010900A (es) 2024-09-17
WO2023170065A1 (en) 2023-09-14
JP2025509278A (ja) 2025-04-11
CA3253688A1 (en) 2023-09-14
IL315441A (en) 2024-11-01
TW202337469A (zh) 2023-10-01
EP4489756A1 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR133027A1 (es) Composición farmacéutica que comprende un compuesto de quinazolina
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
PE20242201A1 (es) Tratamiento de neurofibromas cutaneos con mirdametinib
CL2022001353A1 (es) Inhibidores de egfr
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
ECSP055854A (es) Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa
AR131842A1 (es) Métodos para tratar gliomas
CO2021011319A2 (es) Tratamientos combinados para su uso en el tratamiento del cáncer
MX2022012707A (es) Metodos de tratamiento del sindrome respiratorio agudo grave.
MX2023010849A (es) Métodos de tratamiento.
AR133820A1 (es) Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1
UY39593A (es) Tratamiento para tumores sólidos malignos
AR132852A1 (es) Combiterapia para tratar el cáncer
CL2024003468A1 (es) Inhibidores de ripk1 y métodos de uso.
AR134205A1 (es) Inhibidores de ripk1 y métodos de uso
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
CL2024003598A1 (es) Derivados de piperazina y uso en la terapia contra el vih.
AR134266A1 (es) Métodos para tratar el cáncer utilizando compuestos que inhiben la pkmyt1
MX2025008259A (es) Inhibidores de prmt5-mta
AR123802A1 (es) Tratamientos del angioedema